Search | IOVS | ARVO Journals

Showing 1 – 16 of 16

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2021

COVID-19 pandemic lockdown international impact on nAMD, DME and RVO intravitreal therapy outcomes: Fight Retinal Blindness International registry

Javier Zarranz-Ventura; Vuong Nguyen; Catherine P Creuzot Garcher; Frank D Verbraak; Louise OToole; Alessandro Invernizzi; Francesco Viola; David Squirrell; Daniel Barthelmes; Mark C Gillies

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):311. doi:

ARVO Annual Meeting Abstract June 2020

Epidemiology of acute endophthalmitis after ophthalmological procedures, a national database description

Florian BAUDIN; Eric Benzenine; Anne-Sophie Mariet; Alain M Bron; Catherine Quantin; Catherine P Creuzot Garcher

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):2307. doi:

ARVO Annual Meeting Abstract June 2020

Novel missense mutations in PRPF6 cause autosomal dominant retinitis pigmentosa with incomplete penetrance and impairment of PRPF6 protein localization within the nucleus

Guillaume OLIVIER; Beatrice BOCQUET; Carlo Rivolta; Ervann Andreo; Agnes Muller; Christian Hamel; Alice MASUREL; Catherine P Creuzot Garcher; Laurence FAIVRE; Isabelle Anne Meunier; Gael Manes

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):2401. doi:

ARVO Annual Meeting Abstract June 2020

Association between anatomical and clinical outcomes in patients treated with anti-vascular endothelial growth factor for neovascular age-related macular degeneration

Mark C Gillies; Vuong Nguyen; Calvo Pilar; Martin Puzo; Pierre-Henry GABRIELLE; Catherine P Creuzot Garcher; Florian Baudin; Benjamin Wolff; Louise O’ Toole; Laurent Castelnovo; Michel Guillaume; Daniel Barthelmes

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):4214. doi:

ARVO Annual Meeting Abstract June 2020

Ranibizumab or Aflibercept for Diabetic Macular Edema: One-Year Comparison of Real-World Outcomes from Fight Retinal Blindness! Registry.

SANJEEB BHANDARI; Vuong Nguyen; Samantha Fraser-Bell; Hemal Mehta; Francesco Viola; Florian Baudin; Pierre-Henry Gabrielle; Catherine P Creuzot Garcher; Mark C Gillies; Daniel Barthelmes

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):3289. doi:

ARVO Annual Meeting Abstract July 2018

Quantitative metrics in Swept Source-Optical Coherence Tomography in healthy eyes: fractal dimension, an interesting tool?

Louis Arnould; Pierre-Henry GABRIELLE; Florian Baudin; Behzad Aliahmad; Marc Sarossy; Alain M Bron; Catherine P Creuzot Garcher

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):2885. doi:

ARVO Annual Meeting Abstract July 2018

Development and validation of a risk-prediction nomogram for poor functional response one year after treatment with anti-VEGF in naive-diabetic macular edema.

Pierre-Henry GABRIELLE; Jacques Bouche-Pillon; Edouard Maupin; Serge Aho-Glele; Ramin Tadayoni; Laurent Kodjikian; Alain M Bron; Pascale Massin; Catherine P Creuzot Garcher

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):3615. doi:

ARVO Annual Meeting Abstract June 2017

Real-world outcomes with ranibizumab 0.5 mg treatment in French patients with visual impairment due to diabetic macular edema: 12-month results from the 36-month BOREAL-DME study

Catherine P Creuzot Garcher; Pascale Massin; Laurent KODJIKIAN; Jean-Francois Girmens; Cecile DelCourt; Frank Fajnkuchen; Agnès Glacet; Pierre-Jean Guillausseau; Audrey Derveloy; Laetitia FINZI; Patrick Blin; BPE Team

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1915. doi:

ARVO Annual Meeting Abstract June 2017

Real-world outcomes with ranibizumab 0.5 mg treatment in French patients with visual impairment due to macular edema secondary to central retinal vein occlusion: 6-month results from the 24-month BOREAL-CRVO study

Mayer Srour; Agnès Glacet; Jean-Francois Girmens; Laurent KODJIKIAN; Cecile DelCourt; Frank Fajnkuchen; Catherine P Creuzot Garcher; Pascale Massin; Pierre-Jean Guillausseau; Anne Ponthieux; Laetitia FINZI; Angela Grelaud-Boussinot; BPE Team

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4630. doi:

ARVO Annual Meeting Abstract June 2017

A Pharmacoepidemiological study of intravitreal drug consumption in the first 12 months of treatment. The EPIdemiology and SAFEty collaboration.

Vincent Daien; Catherine P Creuzot Garcher; Marie-Noëlle Delyfer; Alain M Bron; Mark C Gillies; Sandy Lacombe; Laurence Papinaud; Dominique Cholley; Caroline Domerg; Audrey Cougnard-Gregoire; Catherine Quantin; Max Villain; Jean Pierre Daures; Cecile DelCourt; Jean-Francois Korobelnik

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):902. doi:

ARVO Annual Meeting Abstract June 2017

A pro-diabetic diet triggers early functional and structural changes in the rat retina

Elisa Vidal; Elise Lalarme; Laurence Decocq; Marie-Annick Maire; Jeannine Lherminier; Magalie Thierry; Alain M Bron; Catherine P Creuzot Garcher; Niyazi Acar; Lionel Bretillon

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):5867. doi:

ARVO Annual Meeting Abstract June 2017

Role of 24-S-hydroxycholesterol in membrane dynamics during retinal gliosis in glaucoma.

Pierre-Henry GABRIELLE; Ségolène Gambert; Lionel Bretillon; Alain M Bron; Catherine P Creuzot Garcher

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):5385. doi:

Retina October 2012

Single Nucleotide Polymorphism in the Cholesterol-24S-Hydroxylase ( CYP46A1 ) Gene and Its Association with CFH and LOC387715 Gene Polymorphisms in Age-Related Macular Degeneration

PDF

Cynthia Fourgeux; Brice Dugas; Florence Richard; Ingemar Björkhem; Niyazi Acar; Alain M. Bron; Jean-François Korobelnik; Nicolas Leveziel; Jennyfer Zerbib; Nathalie Puche; Catherine P. Creuzot-Garcher; Eric Souied; Lionel Bretillon
TAGS: age-related macular degeneration, cholesterol, genes, hydroxycholesterols, mixed function oxygenases, polymorphism, single nucleotide polymorphism, plasma, alleles
Invest. Ophthalmol. Vis. Sci.. 2012; 53(11):7026-7033. doi: https://doi.org/10.1167/iovs.12-9652

ARVO Annual Meeting Abstract March 2012

Effect of a new Audible and Visual Reminder Device on Adherence with Topical Latanoprost for Glaucoma

Manuel M. Hermann; Alain M. Bron; Catherine P. Creuzot-Garcher; Michael Diestelhorst

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):5108. doi:

ARVO Annual Meeting Abstract March 2012

Comparative Study Of Post-natal Retinal Vascular Development In Mice Models Of iPLA2 Inhibition And Plasmalogen Deficiency

Sarah Saab; Bénédicte Buteau; Laurent Leclère; Catherine P. Creuzot-Garcher; Alain M. Bron; Lionel Bretillon; Niyazi Acar

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):1626. doi:

ARVO Annual Meeting Abstract April 2011

Ultrastructural Changes In The Outer Retina And Retinal Pigment Epithelium Of The ApoB100,LDLR-/- Mouse, A Murine Model Of Aging Of The Human Retina

Lionel Bretillon; Emilie Simon; Bernadette Kantelip; Joël Michel; Niyazi Acar; Alain M. Bron; Jeannine Lherminier; Catherine P. Creuzot-Garcher

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):957. doi:

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

COVID-19 pandemic lockdown international impact on nAMD, DME and RVO intravitreal therapy outcomes: Fight Retinal Blindness International registry

Epidemiology of acute endophthalmitis after ophthalmological procedures, a national database description

Novel missense mutations in PRPF6 cause autosomal dominant retinitis pigmentosa with incomplete penetrance and impairment of PRPF6 protein localization within the nucleus

Association between anatomical and clinical outcomes in patients treated with anti-vascular endothelial growth factor for neovascular age-related macular degeneration

Ranibizumab or Aflibercept for Diabetic Macular Edema: One-Year Comparison of Real-World Outcomes from Fight Retinal Blindness! Registry.

Quantitative metrics in Swept Source-Optical Coherence Tomography in healthy eyes: fractal dimension, an interesting tool?

Development and validation of a risk-prediction nomogram for poor functional response one year after treatment with anti-VEGF in naive-diabetic macular edema.

Real-world outcomes with ranibizumab 0.5 mg treatment in French patients with visual impairment due to diabetic macular edema: 12-month results from the 36-month BOREAL-DME study

Real-world outcomes with ranibizumab 0.5 mg treatment in French patients with visual impairment due to macular edema secondary to central retinal vein occlusion: 6-month results from the 24-month BOREAL-CRVO study

A Pharmacoepidemiological study of intravitreal drug consumption in the first 12 months of treatment. The EPIdemiology and SAFEty collaboration.

A pro-diabetic diet triggers early functional and structural changes in the rat retina

Role of 24-S-hydroxycholesterol in membrane dynamics during retinal gliosis in glaucoma.

Single Nucleotide Polymorphism in the Cholesterol-24S-Hydroxylase ( CYP46A1 ) Gene and Its Association with CFH and LOC387715 Gene Polymorphisms in Age-Related Macular Degeneration

Effect of a new Audible and Visual Reminder Device on Adherence with Topical Latanoprost for Glaucoma

Comparative Study Of Post-natal Retinal Vascular Development In Mice Models Of iPLA2 Inhibition And Plasmalogen Deficiency

Ultrastructural Changes In The Outer Retina And Retinal Pigment Epithelium Of The ApoB100,LDLR-/- Mouse, A Murine Model Of Aging Of The Human Retina

To View More...

You must be signed into an individual account to use this feature.